Abstract
Objective: A novel technology to generate patient-specific organoid cultures derived from adult stem cells, or HUB Organoids™ has gained widespread interest for its application in the development of new therapies and as a predictive diagnostic tool. In this study we aim to utilize CF patient-derived HUB Organoids to identify the combinatory treatment effect of read-through agent, correctors and potentiator on rare mutations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
